Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL1-CD33 cCAR in High Risk Hematologic Malignancies
NCT03795779Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Mar 2018
- Primary completion
- Sep 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLL1-CD33 compound CAR T cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN) and 1 more, sponsored by iCell Gene Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days, Type of Dose Limiting Toxicity at 28 days and 1 more. Status: unknown.
02
Drugs
CLL1-CD33 compound CAR T cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03795779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795779.